CXCL10 and metabolic dysfunction-associated steatohepatitis: MiR-223 plays a key role in controlling steatosis-to-NASH progression by inhibiting expression of Cxcl10 and transcriptional co-activator with PDZ-binding motif (Taz) in the liver (72).